The impact of helicobacter pylori infection in dyspepsia in low dose Aspirin takers

Aspirin (ASA) and helicobacter pylori infection are two major known risk factors for peptic-ulcer. This research aims to examine the interaction between helicobacter pylori and low dose ASA in inducing gastro-intestinal complications. The target group consisted of patients with cardiovascular disease who were under low dose ASA therapy. Patients, who had symptoms of dyspepsia, were placed in the case group and those who did not have these symptoms were placed in the control group. 5cc blood samples, required for conducting ELISA Ab., were taken simultaneously in both of the groups. ELISA positive patients underwent UBT test. UBT positive patients were categorized as helicobacter pylori positive and those with negative UBT were placed in the helicobacter pylori negative group. Finally, the ratio of dyspepsia incidence probability to Aspirin usage and helicobacter pylori infection was analyzed. Of the 129 individuals present in the control group and 71 individuals who were in the case group, 72(36%) were UBT positive, and the rest were UBT negative. Of all the patients, 35.5% had dyspepsia and there was a significant difference between UBT positive and UBT negative individuals (p=0.001, OR=6.54). of 43 patients who had signs of intensified dyspepsia 23 persons under went endoscopy assessment which 20 of them were diagnosed with peptic ulcer. Eighty percent of the patients who had developed peptic ulcer, were UBT positive which revealed a significant difference with UBT negative (p=0.001, OR=8.86). In order to reduce gastro-intestinal complications, it is suggested that long term low dose Aspirin takers be subjected for screening and to receive treatment in terms of infection with helicobacter pylori and clinical manifestations.